



November 7, 2017

Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York City

HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq: ARDM) (the "Company") announced today that it will host a Key Opinion Leader (KOL) Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (NCFBE) on Thursday, November 9, 2017 from 8:00-9:30 am Eastern Time in New York, NY. The breakfast meeting will feature a presentation by Prof. James Chalmers (University of Dundee, UK) who will discuss the current standard of care for patients with NCFBE, the unmet medical need - especially in patients with chronic lung infections with *Pseudomonas aeruginosa*, and the role of inhaled antibiotics to achieve the goals of management of these patients. Prof. Chalmers will be available at the conclusion of the breakfast to answer questions.

Prof. James Chalmers is the British Lung Foundation Professor of Respiratory Research at the University of Dundee, Scotland. He did his undergraduate training in Glasgow and trained in Respiratory Medicine in Edinburgh before moving to Dundee, Scotland. He is a Consultant Respiratory Physician and runs the regional bronchiectasis service that cares for more than 600 patients with the disease, as well as having an active clinical interest in COPD, severe asthma and cystic fibrosis. He has published more than 150 peer reviewed publications and books. He chairs the European Bronchiectasis Registry and recently chaired the European Respiratory Society guidelines for bronchiectasis. In recognition of Professor Chalmers as an outstanding international leader of lung research, in 2017 he received the prestigious award by the British Lung Foundation to advance research on bronchiectasis. He also received the Romain Pauwels award, the highest scientific award from the European Respiratory Society, and the Patrick Neill Medal from the Royal Society of Edinburgh in 2017 for his contributions to bronchiectasis.

Following the presentation by Prof. Chalmers, Aradigm's management team will provide an update on the market opportunity, additional clinical study analyses and regulatory status of the Company's Linhaliq™ candidate product.

Attendance at the KOL Meeting is limited to institutional investors, investment bankers and analysts. To reserve a space, please contact LifeSci Advisors, LLC at mac@lifesciadvisors.com.

The presentations, followed by a question-and-answer session, will be webcast live beginning at 8:00 am Eastern Time. The webcast will be accessible live and archived on the Investor Relations section of Aradigm's website at www.aradigm.com.

About Non-Cystic Fibrosis Bronchiectasis

Non-cystic fibrosis bronchiectasis (NCFBE) is a severe, chronic and rare disease characterized by abnormal dilatation of the bronchi and bronchioles, frequently associated with chronic lung infections. It is often a consequence of a vicious cycle of inflammation, recurrent lung infections, and bronchial wall damage. NCFBE represents an unmet medical need with high morbidity and mortality that affects more than 150,000 people in the U.S. and over 200,000 people in Europe. NCFBE patients who have chronic infections with *P. aeruginosa* have a 6.5-fold increase in hospitalization, three times higher mortality, and a worse quality of life compared with those without *P. aeruginosa* infections. There is currently no drug approved for the treatment of this condition.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Aradigm has completed two Phase 3 clinical trials with Linhaliq, an investigational proprietary formulation of ciprofloxacin for inhalation, for the treatment of NCFBE and submitted an NDA to the FDA for this indication. The PDUFA goal date for completion of the FDA review of the Linhaliq NDA is January 26, 2018. Aradigm's inhaled ciprofloxacin formulations, including Linhaliq, are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria (NTM), and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Forward-Looking Statements

Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including the risk that Linhaliq may not receive regulatory approval or be successfully

commercialized, as well as the other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2016 filed with the SEC on March 30, 2017, and the Company's Quarterly Reports on Form 10-Q.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation. Linhaliq is a registered trademark of Grifols, S.A.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20171107005623/en/>

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

Source: Aradigm Corporation

News Provided by Acquire Media